Breaking News, Collaborations & Alliances

Genmab, Lundbeck Enter Antibody Pact

Genmab has entered an agreement with H. Lundbeck to create and develop human antibody therapeutics for central nervous system (CNS) disorders for three targets identified by Lundbeck.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genmab has entered an agreement with H. Lundbeck to create and develop human antibody therapeutics for central nervous system (CNS) disorders for three targets identified by Lundbeck. Lundbeck will have access to Genmab’s antibody creation and development capabilities, including its automated preclinical antibody screening and characterization and its stabilized IgG4 and UniBody therapeutic antibody platforms. Lundbeck will have an option to select antibodies for clinical development subje...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters